Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSI-301 in wAMD, DME, and RVO
NCT03790852Phase 1Terminated
- Sponsor
- Kodiak Sciences
- Start
- Dec 2018
- Primary completion
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tarcocimab tedromer in exudative macular degeneration, diabetic macular edema (DME) and retinal vein occlusion (RVO) (2 arms), sponsored by Kodiak Sciences. Primary endpoint: Incidence of ocular (study eye) and systemic adverse events at Week 72. Started Dec 2018; status: terminated.
02
Drugs
tarcocimab tedromer
03
Conditions
exudative macular degenerationdiabetic macular edema (DME)retinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT03790852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03790852.